SecBot SecBot
PRESS-RELEASE ·Filed Mar 4, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

No immediate trading implications; monitor for upcoming clinical data readouts or regulatory filings for ficerafusp alfa, which remain the key value drivers for BCAX.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$18.54
T+0 close · Mar 4, 2026 · via day close
Latest settled
+17.31%
T+60 · $21.75
Vs SPY
+7.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $18.54entry
  2. T+1 · 9mo ago −0.22%α +0.36% · $18.50
  3. T+5 · 8mo ago +7.34%α +8.67% · $19.90
  4. T+20 · 8mo ago +10.57%α +14.99% · $20.50
  5. T+60 · 6mo ago +17.31%α +7.23% · $21.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bicara Therapeutics granted a stock option to purchase 115,000 shares to a new employee as an inducement to employment, issued outside its shareholder-approved equity plans under the newly adopted 2026 Inducement Plan. The move is routine for new hires and does not reflect material financial or clinical developments.

Key Facts

  • Bicara Therapeutics issued a stock option to purchase 115,000 shares to a new employee on March 2, 2026.
  • Exercise price of $17.59 equals the Nasdaq closing price on the grant date.
  • Vesting: 25% on first anniversary, remainder in 12 equal quarterly installments.
  • Grant made under the 2026 Inducement Plan, approved by independent directors per Nasdaq Rule 5635(c)(4).
  • No financial results, FDA decisions, or clinical updates were included in the release.

Financial Impact

Minimal near-term financial impact; potential for minor dilution upon exercise of 115,000 options (~0.12% of current market cap assuming $17.59 strike).

dilutionequity compensation

Risk Factors

  • Potential shareholder dilution over time if inducement grants become frequent.
  • No near-term catalysts announced; stock may drift without clinical or regulatory news.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249366

Track record

26 reports on BCAX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
  2. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  3. Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  4. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
  7. Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
  8. Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
  9. Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026